Capstone Investment Advisors
NTLA icon

Capstone Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

Capstone Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-108,665
Closed -$773K – 1697
2025
Q1 		$773K Hold
108,665
– – ﹤0.01% 956
2024
Q4 		$1.27M Buy
108,665
+47,536
+78% +$742K ﹤0.01% 984
2024
Q3 		$1.26M Buy
61,129
+831
+1% +$19.2K ﹤0.01% 889
2024
Q2 		$1.35M Buy
+60,298
New +$1.44M ﹤0.01% 863
2024
Q1 		– Sell
-59,380
Closed -$1.81M – 2481
2023
Q4 		$1.81M Buy
59,380
+10,048
+20% +$289K 0.01% 839
2023
Q3 		$1.56M Buy
49,332
+38,164
+342% +$1.48M 0.01% 814
2023
Q2 		$455K Buy
+11,168
New +$453K ﹤0.01% 1199

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's NTLA Position: Q2 2025 in Review

Capstone Investment Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 108,665 shares — an estimated $773K sold.

Capstone Investment Advisors first reported a position in NTLA in Q2 2023 and held it in 7 quarters. The position peaked at $1.81M in Q4 2023. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Capstone Investment Advisors reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 108,665 Intellia Therapeutics shares in Q2 2025, an estimated $773K.
  • Capstone Investment Advisors first reported a position in Intellia Therapeutics in Q2 2023 and held it in 7 quarters.
  • Capstone Investment Advisors's Intellia Therapeutics position peaked at $1.81M in Q4 2023.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Capstone Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.